MedTrace Logo

AMG 827 in Subjects With Psoriatic Arthritis

NCT01516957 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2020-08-27

Study results available
· View outcomes & findings →

Summary

The study will examine the safety and effectiveness of AMG 827 for the treatment of psoriatic arthritis

Conditions

Interventions

DRUG

AMG 827 140

140 mg AMG 827 SC (subcutaneous)

DRUG

Placebo

Placebo SC (subcutaneous)

DRUG

AMG 827 280

280 mg AMG 827 SC (subcutaneous)

DRUG

AMG 827 210

210 mg AMG 827 SC (subcutaneous)

Sponsors & Collaborators

  • Bausch Health Americas, Inc.

    lead INDUSTRY

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2012-09-30
Completion
2015-09-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01516957 on ClinicalTrials.gov